| Literature DB >> 21085712 |
Sarah Donegan1, Paula Williamson, Carrol Gamble, Catrin Tudur-Smith.
Abstract
BACKGROUND: The indirect comparison of two interventions can be valuable in many situations. However, the quality of an indirect comparison will depend on several factors including the chosen methodology and validity of underlying assumptions. Published indirect comparisons are increasingly more common in the medical literature, but as yet, there are no published recommendations of how they should be reported. Our aim is to systematically review the quality of published indirect comparisons to add to existing empirical data suggesting that improvements can be made when reporting and applying indirect comparisons. METHODOLOGY/Entities:
Mesh:
Year: 2010 PMID: 21085712 PMCID: PMC2978085 DOI: 10.1371/journal.pone.0011054
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of quality assessment criteria.
| Criteria | Yes (%) | No (%) | Unclear (%) | Not applicable |
|
| ||||
| Is the method applied to undertake the indirect comparison adequate? | 41 (95) | 2 (5) | 0 (0) | 0 |
| If an adequate method is used, is a treatment effect estimate and measure of precision reported? | 25 (61) | 16 (39) | 0 (0) | 2 |
|
| ||||
| Is the assumption of similarity stated? | 11 (26) | 32 (74) | 0 (0) | 0 |
| Is a method described to assess the similarity assumption within the review | 0 | 43 (100) | 0 (0) | 0 |
| Is a reasonable approach used to assess the assumption of similarity? | 19 (44) | 22 (51) | 2 (5) | 0 |
| Are patient or trial characteristics reported for all trials in the indirect comparison? | 38 (88) | 5 (12) | 0 (0) | 0 |
| Are patient or trial characteristics compared across the two trial sets involved in the indirect comparison? | 11 (26) | 32 (74) | 0 (0) | 0 |
| Are patient or trial characteristics reported to be comparable for the two trial sets involved in the indirect comparison? | 4 (9) | 5 (12) | 34 (79) (2 unclear if comparable; 32 not reported) | 0 |
|
| ||||
| Is the method used to determine the presence of statistical heterogeneity adequate? | 24 (60) | 12 (30) | 4 (10) | 3 |
| Is the homogeneity assumption satisfied or is statistical heterogeneity accounted for if present? | 19 (48) (8 homogeneous; 11 accounted) | 3 (8) | 18 (45) (17 unclear if homogeneous; 1 unclear if accounted) | 3 |
| If the homogeneity assumption is not satisfied, is clinical or methodological homogeneity across trials in each trial set involved in the indirect comparison investigated by an adequate method? | 12 (38) | 19 (59) | 1 (3) | 11 |
|
| ||||
| Is consistency of effects assessed?(7) | 6 (35) (1used statistical method) | 11 (65) | 0 (0) | 26 |
| If the direct and indirect evidence is reported to be consistent, is the evidence combined and the result presented? | 1 (25) | 3 (75) | 0 (0) | 39 |
| If inconsistency is reported, is this accounted for by not combining the direct and indirect evidence? | 2 (100) | 0 (0) | 0 (0) | 41 |
| Are patient or trial characteristics compared between direct and indirect evidence trials?(10) | 5 (29) | 12 (71) | 0 (0) | 26 |
| Are patient or trial characteristics for direct and indirect evidence trials reported to be comparable?(11) | 2 (12) | 1 (6) | 14 (82) (2 unclear if comparable; 12 not reported) | 26 |
| Are any included 3-arm trials correctly analysed? | 3 (25) | 9 (75) | 0 (0) | 31 |
| Is justification given for using indirect evidence and direct evidence?(13) | 8 (47) | 9 (53) | 0 (0) | 26 |
| Does the review present results from all trials providing direct evidence ?(14) | (65) | 6 (35) | 0 (0) | 26 |
|
| ||||
| Is a distinction made between direct comparisons and indirect comparisons? | 25 (58) | 18 (42) | 0 (0) | 0 |
| Does the review state that more trials providing direct evidence are needed? | 24 (56) | 19 (44) | 0 (0) | 0 |
|
| ||||
| Does the review present both of the meta-analysis results from each of the two trial sets involved in the indirect comparison? | 37 (86) | 6 (14) | 0 (0) | 0 |
| Was it highlighted which results were from indirect evidence? | 24 (56) | 19 (44) | 0 (0) | 0 |
| Are the individual trials' treatment effect estimates reported? | 23 (53) | 20 (47) | 0 (0) | 0 |
Yes: method preserves randomization. No: method does not preserve randomization.
Yes: reported a method that is stated will assess the assumption of similarity. No: do not report a method.
Yes: sensitivity analysis, subgroup analysis, or meta-regression used to assess consistency of the indirect comparison across different trial or patient characteristics. No: no method, no analysis that includes all the trials in the indirect comparison. Unclear: unclear if the trials used in the analysis are the same trial sets involved in the indirect comparison.
Yes: Chi-square test, I-squared statistic, estimating the between trial variance from a random effects models. No: no method applied, or not applied to the two trial sets contributing to the indirect comparison. Unclear: unclear if heterogeneity was assessed for the two trial sets contributing to the indirect comparison. Not applicable: only one trial in each trial set.
Yes: no heterogeneity present (reported by authors or determined from the results), or accounted for heterogeneity using the random effects model. No: heterogeneity not accounted for using the random effects model. Unclear: unclear if heterogeneity present, or unclear if heterogeneity taken into account using the random effects model. Not applicable: only one trial in each trial set.
Yes: sensitivity analysis, subgroup analysis, or meta-regression used to assess homogeneity across different trial or patient characteristics within each of the two trials sets involved in the indirect comparison. No: no method, no analysis that includes the trials in each of the two trial sets involved in the indirect comparison. Unclear: unclear if the trials used in the sensitivity analysis, subgroup analysis, or meta-regression are the same set of trials as those in each of the two trial sets involved in the indirect comparison. Not applicable: only one trial in each trial set; or homogeneity assumption satisfied.
Not applicable: both indirect and direct evidence are not presented for the same comparison.
Not applicable: reported to be inconsistent, or unclear if consistent based on text or results.
Not applicable: reported to be consistent, or unclear if inconsistent based on text or results.
Yes: three-arm trials are correctly analysed i.e. indirect evidence (AC, BC) is not included and direct evidence (AB) is analysed, and data from a three-arm trial is not combined as though it is from two different studies. No: three-arm trials are incorrectly analysed i.e. indirect evidence (AC, BC) is included and direct evidence (AB) is not analysed, or data from a three-arm trial is combined as though it is from two different studies. Na: no three-arm trials are included in the review.
Yes: the term indirect comparison is stated when referring to the result or the result is presented under a heading that states the result is based on an indirect comparison. No: result is presented without noting it is an indirect comparison.
Figure 1Selection process for reviews. Abbreviations: RCTs (randomised controlled trials).
Figure 2Frequency of published reviews including indirect comparisons, by year of publication.
Phrasing of the similarity assumption.
| Review | Phrasing of the similarity assumption |
| Berner 2006 | “The chosen procedure bases on the assumption, that agents are comparable through their relative effect vs. a common comparator” (methods). |
| Boonen 2007 | “The validity of an adjusted indirect comparison depends on the internal validity of the RCTs involved. The methodology assumes similarity in trial design and methodological quality. Another assumption is that the magnitude of the treatment effect is consistent in patients across different trials” (discussion). |
| Chou 2006 | “that the relative effect of one treatment compared with another is consistent across the entire set of trials” (introduction). |
| Clark 2004 | “For the adjusted indirect comparison to be valid, the key underlying assumption is that the relative efficacy of an intervention is consistent in patients included in different trials; that is, that the estimated relative efficacy is generalisable” (results). |
| Collins 2007 | “However, this method is only valid when the magnitude of the treatment effect is consistent between the different studies being compared” (appendix). |
| Hochberg 2003 | “The authors did note that there were several assumptions that should be fulfilled in order to support the inferences drawn from these comparisons, including similarity of methodology in trial design and measurement of clinically important outcomes, and consistency of treatment effect in different subgroups of patients” (discussion). |
| Jones 2004 | “However, the method is only valid when the magnitude of the treatment effect is consistent between the different studies being compared” (results). |
| Lim 2003 | “The validity of indirect comparison meta-analysis is built on the assumption that no important differences exist between trials examining medium or low dose regimens. If the two sets of trials differ with respect to a feature (clinical or methodological) that modified the treatment effect, then the comparisons of medium and low dose aspirin would be confounded” (discussion). |
| Otoul 2005 | “In order for this indirect comparison to be valid, the overall characteristics of the trials included in the meta-analyses could not differ systematically. The main statistical assumption in this adjusted method is that the relative effect of a drug is consistent; i.e., the odds ratio is the same in patients included in different trials” (methods). |
| Sauriol 2001 | “The indirect approach to meta-analysis requires certain conditions to yield optimal results. For example, it is important that study designs, patient inclusion/exclusion criteria, and patient characteristics at baseline are as similar as possible across studies. Heterogeneity in study design or study population can lead to heterogeneity in results, and may lead to nonvalid conclusions. Therefore, the use of such methods does not always lead to the same conclusions” (discussion). |
| Zhou 2006 | “The presence of clinical heterogeneity in these trials was evident; however, results from meta-analysis and substudies, particularly those using individual patient data, have indicated that the RR reduction of cardiovascular events by statin did not depend on the patients' risk stratified by age, sex, CHD history, and other cardiovascular risk factors. This consistency in the effect across different baseline characteristics is also required by the method of adjusted indirect comparison to ensure valid results” (discussion). |